Poor Mobilization-Associated Factors in Autologous Hematopoietic Stem Cell Harvest.

Simple Summary: This study aims to describe the factors associated with poor mobilization in patients undergoing autologous peripheral blood stem cell harvest. Poor mobilization was observed in 30.5% of the patients included in the investigation. While older age, myelotoxic agents, and low platelet counts were associated with poor mobilization in patients with hematologic diseases, a history of radiation therapy to the spine and pelvic region was associated with mobilization failure in patients with non-hematologic diseases. In patients who received plerixafor, 14.2% suffered from mobilization failure, with differences in hemoglobin, platelet counts, and mobilization regimens noted between the poor and good mobilization groups. Identifying potential risk factors for poor mobilization in specific groups of patients will aid in planning therapy and ensuring successful transplantation in those requiring hematopoietic stem cell transplants. Peripheral blood stem cell transplantation (PBSCT) is an important therapeutic measure for both hematologic and non-hematologic diseases. For PBSCT to be successful, sufficient CD34⁺ cells need to be mobilized and harvested. Although risk factors associated with poor mobilization in patients with hematologic diseases have been reported, studies of patients with non-hematologic diseases and those receiving plerixafor are rare. To identify factors associated with poor mobilization, data from autologous PBSC harvest (PBSCH) in 491 patients were retrospectively collected and analyzed. A multivariate analysis revealed that in patients with a hematologic disease, an age older than 60 years (odds ratio [OR] 1.655, 95% confidence interval [CI] 1.049–2.611, p = 0.008), the use of myelotoxic agents (OR 4.384, 95% CI 2.681–7.168, p < 0.001), and a low platelet count (OR 2.106, 95% CI 1.205–3.682, p = 0.009) were associated with poor mobilization. In patients with non-hematologic diseases, a history of radiation on the pelvis/spine was the sole associated factor (OR 12.200, 95% CI 1.934–76.956, p = 0.008). Among the group of patients who received plerixafor, poor mobilization was observed in 19 patients (19/134, 14.2%) and a difference in the mobilization regimen was noted among the good mobilization group. These results show that the risk factors for poor mobilization in patients with non-hematologic diseases and those receiving plerixafor differ from those in patients with hematologic diseases; as such, non-hematologic patients require special consideration to enable successful PBSCH. [ABSTRACT FROM AUTHOR]